ATO exerts anti-osteosarcoma effects by inhibiting UBE2O-mediated L3MBTL2 degradation, while arborinine blocks UBE2O’s degradation of substrates like AMPKα2 and demonstrates synergistic chemotherapeutic potential in breast and liver cancer models. This evidence concerns the gene L3MBTL2 and liver cancer.